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Abstract
Background: The purpose of this study was to deter-
mine the positive predictive value (PPV) of positive
serum human epidermal growth factor receptor-2
(HER-2) for monitoring women with breast cancer fol-
lowing diagnosis and treatment in a routine clinical
setting.
Methods: Serum HER-2 was measured in 1348
patients with breast cancer: 837 during routine oncol-
ogy clinic visits and 511 following new diagnosis. All
patients with positive serum HER-2, 1/5 of negative
patients from the oncology clinic, and all the newly
diagnosed were followed; a total of 862 patients.
Serum HER-2 was measured using the Bayer ADVIA
Centaur assay. Tissue HER-2 was determined using
immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH). IHC q3 or IHC q2 and FISH)2.0
were positive. Patients were considered to have pos-
itive serum HER-2 when at least two values were
)15 ng/mL. Recurrence, progression and regression
were diagnosed according to usual clinical practice.
Serum HER-2 concentrations did not contribute to
diagnostic decision-making or selection of treatment.
Results: From January 2004 to January 2009, 149
patients were found to have positive serum HER-2. Of
these, 35 were tissue HER-2 positive at surgery, 69
tissue-negative and 45 were not determined. Fifty-five
of 149 that were serum HER-2 positive (37%, 95% CI:
29–45) had metastases. Among the 35 tissue-positive
patients, 25 had recurrence in the form of metastases
and there was good correlation between recurrence/
progression and increase in serum HER-2 (p-0.0003).
There was also a high correlation between effect of
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treatment and decline in serum HER-2 (p-0.0003). Of
the 69 tissue-negative patients, 29 had recurrence in
the form of metastases, and there was good correla-
tion with serum HER-2 levels (p-0.000004). In this
routine application of serum HER-2, the PPV for
metastases recurrence detection in both tissue-posi-
tive and tissue-negative was 54 of 104 (52%, 95% CI:
42%–62%), in tissue-positive 25 of 35 (71%, 95% CI:
54%–85%), in tissue-negative 29 of 69 (42%, 95% CI:
30%–54%). The lead time of increases in serum HER-
2 before recurrence could be determined in ten tissue-
positive patients was 3–24 months (mean 11.3
months), when compared to standard clinical imaging
methods.
Conclusions: Serum HER-2 is a useful marker for the
detection of recurrence of breast cancer and for mon-
itoring the effect of treatment, especially in tissue
HER-2 positive patients.
Clin Chem Lab Med 2009;47:1117–23.
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Introduction
The human epidermal growth factor receptor-2 (HER-
2)/neu gene encodes a transmembrane glycoprotein
with tyrosine kinase activity. This glycoprotein medi-
ates proliferation and differentiation in both normal
and cancer cells.
In 20%–25% of patients with breast cancer, the gene
is amplified and detectable by fluorescence in situ
hybridization (FISH). This results in higher than nor-
mal HER-2 receptor protein concentrations in the tis-
sue that is detectable by both immunohistochemistry
(IHC) and protein quantitation by ELISA (1).
HER-2 gene amplification and/or over expression is
associated with poor prognosis (2).
Tissue HER-2 status is commonly determined by
IHC and FISH, where IHC q3 or IHC q2 and FISH)2.0
are considered positive.
It is known that the HER-2 extracellular domain
(ECD) may be cleaved and shed from the surface of
breast cancer cells and released into the circulation
(3).
Circulating concentrations of HER-2 ECD can be
measured in serum. While determination of tissue
HER-2 is a one-time event, serum HER-2 can be meas-
ured any time during follow-up.
The serum HER-2 test using the ADVIA Centaur
assay is approved by the Food and Drug Administra-
tion (FDA) for follow-up and monitoring of patients
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with metastatic breast cancer (MBC) whose initial
serum HER-2 concentration is above 15 ng/mL (4).
The purpose of this study was to determine the pos-
itive predictive value (PPV) of positive serum HER-2




The Regional Science Ethics Committee of Fyns and Vejle
Counties (reg. nr S-VF-20040101) approved the work.
Between January 2004 and January 2009, serum HER-2 was
measured in 1348 patients with breast cancer: 837 during
routine oncology clinic visits and 511 patients that were new-
ly diagnosed. We followed all serum-positive HER-2 patients
(above 15 ng/mL), 1/5 of the serum-negative patients from
the oncology clinic and all of the newly diagnosed patients
(ns862). Patients with only one serum HER-2 measurement
were excluded.
All newly diagnosed and treated patients were followed
after surgery with serum HER-2 at clinically determined time
intervals (3–12-month intervals). Serum HER-2 concentra-
tions did not contribute to diagnostic decision-making or
treatment.
Clinical follow-up and anticancer treatment
Following primary breast cancer surgery, patients were fol-
lowed routinely for relapse by physical examination. If the
patient presented with symptoms of relapse, MR/CT/UL
(Magnetic Resonance Imaging/Computed Tomography/
Ultrasound) and X-ray examination were performed. Meas-
urable and non-measurable disease was documented.
Solitary lesions were verified cytologically and/or histologi-
cally if they indicated the only evidence of disease. A scaled
photograph of skin metastases was taken. Patients with his-
tologically confirmed HER-2 positive (IHC3q or FISHq),
locally advanced or MBC were treated with chemotherapy,
including use of Trastuzumab. Due to the high response
rates found in the phase II study when using a combination
of either Vinorelbine and Trastuzumab or the Taxanes and
Trastuzumab, these regimes were used as first and second
line treatments. The following treatment was used: Trastu-
zumab 6 mg/kg every 3 weeks by intravenous (IV) infusion
over 90 min. Initial dose was 8 mg/kg (loading dose). For
Docetaxel, 100 mg/m2 every 3 weeks IV infusion over 60 min.
For Vinorelbine, 30 mg/m2 IV infusion over 10 min day 1, and
8 mg/m2 every 3 weeks. A few patients with extensive liver
metastases were treated with Trastuzumab and a weekly
dose of Paclitaxel (80 mg/m2). Third line treatment was
Lapatinib-Capecitabine with doses of 1250 mg Lapatinib
and Capecitabine at a dose of 1000 mg/m2 per os (PO) days
1–14, every 21 days. Many of the younger patients received
adjuvant chemotherapy with Antracycline wFEC or EC
(Fluorouracil, Epirubicin, Cyclophosphamide or Epirubicin,
Cyclophosphamide)x.
For patients with HER-2 negative disease, first line che-
motherapy consisted of Docetaxel. If patients had received
adjuvant Antracycline previously, Capecitabine was used as
second line treatment.
Evaluation of response
Measurable disease was evaluated according to response
evaluation criteria in solid tumors (RECIST) (5, 6). All lesions
found at the time of relapse were recorded and followed
using the same methods. Lesions were evaluated by physi-
cal examination (palpable lymph nodes, or skin metastases)
and by MR, CT scanning and X-ray examinations. These
were reviewed every 9th week until progression. Complete
response (CR) or partial response (PR) was confirmed after
at least 4 weeks.
Biochemical analysis
Serum HER-2 was measured using the Bayer Advia Centaur,
XP Immunoassay System Bayer Health Care (Siemens Med-
ical Solutions Diagnostics, Ballerup, Denmark). In brief, the
ADVIA Centaur HER-2 assay is an automated sandwich
immunoassay using direct chemiluminescent technology (1).
CV% in the period was measured using commercial and
in-house control materials at 8, 14 and 113 ng/mL. The CVs
were 6.6, 4.6 and 4.8%, respectively. Tissue HER-2 was deter-
mined using IHC and FISH. In brief, IHC was performed on
formalin-fixed, paraffin-embedded breast tissue sections
using the Hercep Test (DakoCytomation, Glostrup, Den-
mark). FISH was performed on formalin-fixed, paraffin-
embedded breast tissue sections using a HER-2 FISH
pharmDx kit (DakoCytomation) (1). IHC q3 or IHC q2 and
FISH)2.0 was considered positive.
Data analysis
Patients were considered to have positive serum HER-2
when at least two values were )15 ng/mL. One value above
15 ng/mL did not accelerate control visits. Recurrence, pro-
gression and regression were diagnosed according to usual
clinical practices as described above. PR and CR were reg-
istered together as response.
The Mann-Whitney test was used to evaluate statistically
significant differences. We used the NCSS 2004 statistical
package (Number Cruncher Statistical System, Kaysville,
Utah, USA). Predictive values were calculated according to
‘‘Evaluation of test data from clinical studies’’ according to
Gerhardt and Keller (7).
Results
Of the 862 patients, 219 had not been characterized
by tissue HER-2 test at the time of surgery, 437 were
tissue HER-2 negative and 206 were tissue HER-2
positive (IHC 3q, or IHC 2q and FISH)2).
Serum HER-2 was positive in 149 of the 862 patients
(17.2%).
Of the 206 tissue-positive patients, 35 were serum
HER-2 positive during the period (16.9%). Of the 437
tissue-negative patients, 69 were serum HER-2 posi-
tive during the period (15.7%). Of the 219 patients
whose tissue status was unknown, 45 were serum
HER-2 positive during the period (20.5%) (Table 1).
Of the 149 patients with positive serum HER-2, only
35 were tissue-positive, 69 were tissue-negative and
45 were of unknown tissue status (Table 2). Patient
demographics and tumor characteristics of the study
population are shown in Table 3.
Figure 1 shows the highest values reached in IHC
negative and positive patients. Higher concentra-
tions were obtained in tissue-positive patients
(p-0.0000001).
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Table 2 Patients with increased serum HER-2.
Tissue- Tissue- Unknown Total
positive negative tissue status
With relapse 25 29 1
Without relapse 10 40 44
Total 35 69 45 149
Table 1 All patients.
Tissue- Tissue- Unknown Total
positive negative tissue status
Positive serum 35 69 45 149
HER-2
Negative serum 171 368 174 713
HER-2
Total 206 437 219 862
HER-2, human epidermal growth factor receptor-2.
Figure 2 Maximum serum HER-2 values in 69 patients who
were serum HER-2 positive but tissue HER-2 negative,
patients without (ns40) or with relapse/progression (ns29)
(p-0.00004).
In patients negative for HER-2 in tissue and with clinical
relapse or progression, serum HER-2 levels were higher than
in patients without relapse or progression.
Figure 1 Serum HER-2 maximum values in tissue IHC/FISH
negative (ns69) and positive (ns35) patients
(p-0.0000001).
The highest values for serum HER-2 were seen in IHC-tissue
positive patients. Three serum HER-2 values between
3300 ng/mL and 14,000 ng/mL from patients with positive
tissue not shown.
Figure 2 shows the highest values in tissue-nega-
tive patients, with or without relapse in the form of
metastases (p-0.000004). PPV at )15 ng/mL was
29/69s42%. A PPV of 100% was reached at a discrim-
ination level of 25 ng/mL, incorrectly classifying 11 of
29 with relapse (total false negatives 11/29s38%).
Figure 3 shows the highest values obtained in
tissue-positive patients with or without relapse in the
form of metastases (p-0.00003). PPV at )15 ng/mL
was 25/35s71%. Thus, the predictive value of serum
HER-2 is higher in tissue-positive compared with tis-
sue-negative patients, 71% against 42% (p-0.008).
A PPV of 100% was achieved at 32 ng/mL, five
patients were incorrectly classified with 5/25 false
negatives (20%).
Figure 4 shows the increases in delta values in tis-
sue-positive patients, with and without metastases
(p-0.0003). The PPV of 100% corresponds to a dis-
crimination concentration of delta 16 ng/mL, incor-
rectly classifying 7 of 25 patients that developed
metastases.
Figure 5 shows the decreases in delta values in
tissue-positive patients with metastases, with and
without regression (p-0.0003). A PPV of 100% is seen
at a delta decrease of at least 77 ng/mL, incorrectly
classifying 6 of 18 patients.
Figure 6A and B shows seven patients that illustrate
the overall findings from Figures 3–5. These show
increases with disease progression, and decreases
following response to targeted treatment (tissue-
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Figure 3 Maximum serum HER-2 values in 35 patients who
were serum HER-2 positive, tissue HER-2 positive, in patients
without (ns10) or with relapse/progression (ns25).
Three tissue-positive serum HER-2 values between 3300
ng/mL and 14,000 ng/mL are not shown (p-0.00003).
Figure 4 Positive delta values of serum HER-2 are shown
for tissue-positive patients without (ns10) or with progres-
sion to metastases (ns25) (p-0.0003).
Figure 5 Negative delta values in tissue-positive patients
with positive serum HER-2 and metastases without (ns7) or
with (ns17) clinical regression in response to therapy
(p-0.0003).
Patients showing clinical regression had decreasing delta
values as compared to non-responders. One patient with
negative delta value 10,352 and clinical status undetermined
not shown.
Figure 6 Serum HER-2 changes in four patients with clinical
response and regression in metastases.
Serum HER-2 increases in relation to relapse in form of
metastases and decrease in relation to response to therapy
and regression (A). Serum HER-2 changes in three patients
showing response to therapy and primary regression of
metastases but secondary progression. Serum HER-2
increases to high levels in relation to relapse in form of
metastases, decrease in relation to response to therapy and
regression but increase again in relation to progression (B).
The different symbols differentiate between patients and
represent the time of blood sample.
positive patients treated with combinations involving
Trastuzumab).
Figure 7A, B, C shows details in tissue-positive
patients responding or not to treatment.
Figure 8A and B shows details in tissue-negative
patients responding or not to treatment.
Discussion
The primary aim of this project was to investigate the
value of increased serum HER-2 concentrations for
the follow-up of all surgically treated breast cancer
patients, as well as patients treated previously and
followed routinely by the Department of Oncology.
This design could not establish sensitivity and spec-
ificity for relapse or progression to metastases. Only
the predictive value of a positive test, and the test
performance for measuring treatment effects when
serum HER-2 was positive in both tissue-positive and
tissue-negative patients could be investigated.
Patients with negative tissue HER-2 had as great a risk
of developing positive serum HER-2 as did tissue-
positive (69/437 and 35/206) (ps0.74).
This finding is surprising, considering the general
opinion that only tissue-positive patients would devel-
op serum positivity, unless primary tissue classifica-
tion was erroneous, or conversion from non-amplified
cancer cells to amplified had taken place. In our study,
IHC/FISH was performed in both primary tumor and
metastases in two patients; both were negative.
However, our data show that breast cancer, previ-
ously diagnosed as tissue-negative, reach serum
HER-2 concentrations of maximum 200 ng/mL, mean
27.3 ng/mL. Tissue-positive patients achieve maxi-
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Figure 7 Details from tissue-positive patients responding or
not to treatment.
(A) Details from a 59-year-old woman. Surgery 2001. Tissue
HER-2 positive. Nine series FEC. Radiotherapy. August 2007
project medicine Lapatinib or placebo, adjuvant. CT 30.04.08
showed mediastinal and lung metastases. Received 5 series
Trastuzumab-Paclitaxel (15.05.08–08.08.08). Regression of
metastases on CT July 2008. (B) Details from a 57-year-old
woman. Surgery 2005. Tissue HER-2 positive. Seven series
FEC followed by Tamoxifen, adjuvant. Relapse detected
March 2008 when CT showed liver and lung metastases.
Three series Trastuzumab-Vinorelbine (28.03.08–14.05.08).
May 2008 progression. (C) Details from a 55-year-old wom-
an. Surgery 2004. Tissue HER-2 positive. Seven series FEC.
Radiotherapy, adjuvant followed by Trastuzumab
(10.02.06–27.12.06) but in spite of that lung metastases on
CT 29.12.06. Trastuzumab-Docetaxel. March 2007 progres-
sion. Changed to Trastuzumab/Vinorelbine, progression,
changed to Capecitabine, progression.
Figure 8 Details from tissue-negative patients responding
or not to treatment.
(A) Details from a 45-year-old woman. Surgery February
2002. Local relapse June 2004. Tissue HER-2 negative. Sep-
tember 2005 bone metastases. Docetaxel-Capecitabine from
November 2005 to March 2006. Regression on CT 15.12.05.
(B) Details from a 70-year-old woman. Locally advanced
breast cancer. Five series FEC (01.10.04–26.01.05) with little
regression. Five series Docetaxel (18.02.05–19.05.05) with
big regression, surgery 09.06.05. Tissue HER-2 negative.
Relapse in form of liver, lung and bone metastases Novem-
ber 2007. Capecitabine, responsesno change.
mum concentrations of 14,000 ng/mL, mean 224.8
ng/mL (p-0.0000001). We do not believe that the
explanation is either misdiagnosis or conversion. If
this was the case, the serum HER-2 in tissue-negative
patients would have been as high as in tissue-positive
patients. Rather, the moderately increased concentra-
tions reflect dissemination of cancer, which is HER-2
negative, but with an increased tumor load. However,
it will be necessary to perform IHC/FISH on all metas-
tases to clarify this.
It has been suggested that inflammation, infection
or liver disease could slightly increase serum HER-2.
However, we have found no publications to document
this, and this was not seen in our patients as a general
finding. However, for the tissue-positive and negative
patients without metastases, 11 had slightly increased
lactate dehydrogenase (LDH), none with increased
C-reactive protein (CRP), and seven with increased
alanine transaminase (ALT) (ns50).
Further, the large difference in serum HER-2 con-
centrations in tissue-positive and tissue-negative
patients shows that even low values above 20 ng/mL
in tissue-negative patients should be taken seriously.
Also, a concentration of 50 ng/mL in tissue-negative
patients may reflect a metastatic burden correspond-
ing to a level 5–10 times as high in tissue-positive
patients.
Thus, there is also value in following tissue-nega-
tive patients with serum HER-2 measurements as this
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Figure 9 Proposal for serum HER-2 test algorithm.
detects recurrence or metastases with an acceptable
PPV (29 of 69s42%, 95% CI: 30–54).
The design of this investigation only allows deter-
mination of the PPV of increased serum HER-2 con-
centration. Of the 149 serum HER-2 positive patients,
55 had progression or dissemination of disease at a
cut-off of 15 ng/mL, giving a PPV of 37% (95% CI:
29–45), sufficient to decide further clinical investiga-
tion. If the maximum value for patients without
metastases (ns94, 32 ng/mL) is used for the cut-off
threshold, the PPV is 100% (34/34, misclassifying 21
patients, 95% CI: 90%–100%). Repeating these calcu-
lations for the tissue-positive and negative group, the
values were 32 ng/mL (misclassifying 5 patients) and
25 ng/mL (misclassifying 11 patients).
This shows that serum values for patients known to
be tissue-positive should be evaluated differently than
serum values determined in patients that are tissue-
negative. A 100% PPV is reached with a cut-off thresh-
old of 32 ng/mL and 25 ng/mL, respectively. Though
single determinations have value for detecting metas-
tases, monitoring of patients at suitable time intervals
yields further information as shown in Figures 6–8.
As Figure 5 shows, there is an excellent correlation
between CT-determined regression and decreases in
serum HER-2. These findings are also shown for
selected patients (Figure 6) and in detail for individual
patients in relation to treatment (Figures 7 and 8).
Thus, it is not only important to follow-up positive
values, but also moderate continuous increases
should be watched closely (Figure 7B and C).
Other authors have reported similar finding. Esteva
and colleagues (8) evaluated serum HER-2 in 30
women with positive tissue HER-2 MBC who were
undergoing weekly Docetaxel and Trastuzumab ther-
apy. They found that changes in serum HER-2 con-
centrations correlated well with the clinical course.
Kong and colleagues (9) evaluated 195 patients with
MBC and found that the mean serum HER-2 in the
tissue-negative group was significantly lower than
concentrations in the tissue-positive group: 22.2 mg/L
vs. 363 mg/L.
In a review, Carney and colleagues (10) described
that some women with tissue HER-2 negative tumors
developed increased serum HER-2 in metastatic dis-
ease. These findings were originally observed by
Kandl et al. (11) and Molina et al. (12). Kandl and col-
leagues reported that some patients who were nega-
tive for tissue HER-2 developed extremely high serum
HER-2 concentrations during MBC, and that increas-
ing concentrations correlated with progression of
disease.
Gancberg and colleagues (13) compared HER-2
status in primary breast cancer with corresponding
distant metastatic sites from 107 patients. They found
similar degrees of amplification (25% and 24%) and
over expression (13% and 19%). Zidan and colleagues
(14) found concordance in 86% of patients.
Carney and colleagues in another review (4) con-
cluded that one potential clinical use of serum HER-2
was to identify patients with an elevated serum HER-
2 but negative tissue HER-2 because this could be the
reason to re-evaluate the original or a metastatic
tumor by IHC or FISH. They also concluded that the
most probable reason for a patient to be found to be
HER-2 negative is that the patient’s tumor has -10%
3q positive cells required to be considered HER-2
tissue-positive. However, it is likely that there are
enough HER-2 positive cells in the primary tumor to
generate HER-2 positive MBC.
Luftner and colleagues (15) recommend that
patients with HER-2 positive tumors be followed at
3–6-month intervals with serial monitoring of serum
HER-2 concentrations to detect relapse. They also
concluded that determination of serum HER-2 is not
likely to provide clinically useful information for those
patients found to be tissue HER-2 negative. However,
they did recommend that the first measurement of
serum HER-2 be obtained at the time of relapse. This
is in contrast to our findings. We found the same
number of patients with positive serum HER-2 in the
tissue-negative and the tissue-positive group.
Recently, Ardavanis and colleagues (16) treated 22
tissue-negative patients with serum HER-2 concentra-
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tions G15 ng/mL with Trastuzumab and Taxane.
These patients had previously failed at least two lines
of Anthracycline- and Taxane-based regimens. They
observed minor response in five patients and stable
disease in 11.
Recently, Suhail and colleagues (17) retrospectively
analyzed individual pooled data from 307 patients
with MBC treated with first line Trastuzumab-based
therapy. They concluded that patients who did not
achieve a significant decline (G20%) in serum HER-2
concentrations had decreased benefit from Trastuzu-
mab-based therapy.
An important finding is that increases in serum
HER-2 can detect recurrence in form of metastases or
recurrence at an earlier time, before clinical methods.
The lead-time of serum HER-2 increases prior to
detection of recurrence could be determined in ten
tissue-positive patients at 3–24 months (mean
11.3 months). If the decision to treat with targeted
therapy, including Trastuzumab, based on statistically
significant increases in serum HER-2 was taken
earlier, more patients may be expected to survive
longer. Only controlled trials can verify this.
While waiting for control trials to establish recom-
mendations for the use of serum HER-2, we recom-
mend the use of an algorithm as shown in Figure 9
for the detection of recurrence.
Also, the possible value of combining relative delta
values of serum HER-2 concentrations as percent
increases from base levels, or including CA 15-3 and
CEA, should be investigated.
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